Details of the Drug

General Information of Drug (ID: DMW2GEJ)

• Drug Name: Mepolizumab
• Synonyms: Bosatria; Scoparianoside C; SB 240563; Immunoglobulin G1, anti-(human interleukin 5) (human-mouse monoclonal SB-240563 gamma1-chain), disulfide with human-mouse monoclonal SB-240563 kappa-chain, dimer; (2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Severe asthma	CA23	Approved	[1]
Asthma	CA23	Phase 2/3	[2]

• Drug Type: Monoclonal antibody
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 30-60 min [3]
  Bioavailability: The bioavailability of drug is 100% [3]
  Clearance: The sytemic clearance of drug is 0.28 L/day [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 16 - 22 days [4]
  Metabolism: The drug is metabolized via proteolytic degradation at sites distributed throughout the body [4]
  Vd: The volume of distribution (Vd) of drug is 3.6 L [4]
• Cross-matching ID:
  DrugBank ID: DB06612
  TTD ID: D03MTN
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-5 (IL5)	TTPREZD	IL5_HUMAN	Modulator	[5]

Molecular Expression Atlas of This Drug

• The Studied Disease: Severe asthma
• ICD Disease Classification: CA23

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin-5 (IL5)	DTT	IL5	6.51E-01	-0.02	-0.11
Interleukin-5 (IL5)	DTT	IL5	1.71E-04	0.12	0.71

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7685).
• [2] ClinicalTrials.gov (NCT01366521) Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils
• [3] FDA Approved Drug Products: Monoket (isosorbide mononitrate) tablets
• [4] FDA Approved Drug Products: Nucala (mepolizumab) injection
• [5] Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D. 2008;9(2):125-30.